Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Taoka Chemical Company, Limited (4113.T)
Osaka, JP
Operating both domestically in Japan and across global markets, Taoka Chemical Company, Limited specializes in the production and distribution of a diverse array of chemical products. Its extensive portfolio includes essential ingredients for photoresists; diverse adhesives, such as single-component epoxy formulations for various bonding applications and fast-acting cyanoacrylate glues; specialized constituents for electronic devices; and an assortment of varnishes including amide, ester imide, nylon, polyester, and polyimide-based types. The company also provides resins and water-soluble polymers for paper processing; precursor chemicals vital for pharmaceutical and diagnostic applications; and a suite of rubber additives, encompassing cross-linking agents, tackifiers, and specialized kneading-type vulcanizing adhesives. Furthermore, it supplies plasticizers used in food packaging films, flooring, footwear, hoses, inks, rubber gloves, and food cans. Taoka Chemical offers methyl esters, serving as foundational components for industrial detergents, shell molds, and fine chemical intermediates, including aromatic compounds. The firm also produces an array of dyes for textiles, paper, leather, and plastics. Additionally, Taoka Chemical develops and manufactures advanced chemical entities, such as bisphenol derivatives, TBIS (an epoxy derivative), TBIS (an acid dianhydride), episulfide derivatives, and indole derivatives, which find utility as intermediate compounds in medical and agrochemical sectors. Established in 1919, the company initially operated as Taoka Dystuffs Manufacturing Co., Ltd. before adopting its current name, Taoka Chemical Company, Limited, in 1972. It maintains its corporate headquarters in Osaka, Japan, and functions as a subsidiary of Sumitomo Chemical Company, Limited.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -7.71% | -13.65% | -16.16% | -33.33% | -33.73% | -39.22% | -32.99% | +1.17% | -61.52% | +161.95% | +183.94% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Chemicals - Specialty: +4.7%+10.9% ★ Q1'26: +3.5% (vs Q1'25)
-
EPS growth Chemicals - Specialty: +13.2%+3.7% Q1'26: -45.9% (vs Q1'25)
-
FCF margin FCF growth · Chemicals - Specialty: +44.1%+3.6% Q1'26: +0.0% (vs Q1'25)
-
EBIT margin Chemicals - Specialty: +8.8%+6.2% Q1'26: +3.6% (vs Q1'25)
-
ROIC Chemicals - Specialty: +5.6%+8.0% ★ Q1'26: +4.7% (vs Q1'25)
-
Share dilution Chemicals - Specialty: +0.1%+0.0% Q1'26: +0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Chemicals - Specialty: 0.18×0.23× ★ Q1'26: 0.30× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 2019 actual |
Mar 2020 actual |
Mar 2021 actual |
Mar 2022 actual |
Mar 2023 actual |
Mar 2024 actual |
Mar 2025 actual |
Mar 2026 1 Rev. Ana. 1 EPS Ana. |
Mar 2027 1 Rev. Ana. 1 EPS Ana. |
Mar 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
24.46B
est: 24.50B (-0.2%)
|
25.67B
est: 25.70B (-0.1%)
|
32.06B
est: 32.00B (+0.2%)
|
32.37B
est: 32.00B (+1.2%)
|
30.17B
est: 31.00B (-2.7%)
|
28.54B
est: 28.50B (+0.2%)
|
29.93B
est: 29.30B (+2.2%)
|
32.50B
32.50B – 32.50B
+10.9% YoY
|
32.20B
32.20B – 32.20B
-0.9% YoY
|
34.70B
34.70B – 34.70B
+7.8% YoY
|
| EBITDA |
3.92B
est: 2.76B (+42.1%)
|
4.14B
est: 2.90B (+43.0%)
|
5.51B
est: 3.61B (+52.8%)
|
4.18B
est: 3.61B (+16.0%)
|
1.91B
est: 3.49B (-45.2%)
|
2.54B
est: 3.23B (-21.3%)
|
3.37B
est: 2.99B (+12.7%)
|
3.32B
3.32B – 3.32B
+10.9% YoY
|
3.29B
3.29B – 3.29B
-0.9% YoY
|
3.54B
3.54B – 3.54B
+7.8% YoY
|
| EBIT |
2.55B
est: 1.58B (+61.7%)
|
2.69B
est: 1.65B (+62.6%)
|
4.02B
est: 2.06B (+95.0%)
|
2.71B
est: 2.06B (+31.5%)
|
451.06M
est: 2.00B (-77.4%)
|
1.07B
est: 1.85B (-41.9%)
|
1.89B
est: 1.53B (+23.4%)
|
1.70B
1.70B – 1.70B
+10.9% YoY
|
1.68B
1.68B – 1.68B
-0.9% YoY
|
1.81B
1.81B – 1.81B
+7.8% YoY
|
| Net Income |
1.82B
est: 1.90B (-4.2%)
|
1.90B
est: 1.80B (+5.5%)
|
2.62B
est: 2.70B (-3.1%)
|
2.06B
est: 1.95B (+5.8%)
|
310.65M
est: 299.47M (+3.7%)
|
820.48M
est: 650.54M (+26.1%)
|
1.48B
est: 1.25B (+18.3%)
|
1.35B
1.35B – 1.35B
+8.0% YoY
|
1.05B
1.05B – 1.05B
-22.2% YoY
|
1.40B
1.40B – 1.40B
+33.3% YoY
|
| SGA |
2.26B
est: 2.26B (-0.1%)
|
2.27B
est: 2.37B (-4.6%)
|
2.42B
est: 2.96B (-18.2%)
|
2.71B
est: 2.96B (-8.5%)
|
2.71B
est: 2.86B (-5.3%)
|
2.64B
est: 2.48B (+6.7%)
|
2.79B
est: 2.76B (+1.0%)
|
3.07B
3.07B – 3.07B
+10.9% YoY
|
3.04B
3.04B – 3.04B
-0.9% YoY
|
3.27B
3.27B – 3.27B
+7.8% YoY
|
| EPS |
126.98
est: 132.52 (-4.2%)
|
132.41
est: 125.56 (+5.5%)
|
182.58
est: 188.42 (-3.1%)
|
144.04
est: 136.10 (+5.8%)
|
21.68
est: 20.90 (+3.7%)
|
57.26
est: 45.40 (+26.1%)
|
103.15
est: 87.20 (+18.3%)
|
94.20
94.20 – 94.20
+8.0% YoY
|
73.30
73.30 – 73.30
-22.2% YoY
|
97.70
97.70 – 97.70
+33.3% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-15 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-14 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-13 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-12 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-11 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-08 | A | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-07 | A | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-01 | A | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-30 | A | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-28 | A | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-27 | A | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-24 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-23 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-22 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-21 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-20 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-17 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-16 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Avantis International Small Cap Value ETF AVDV | 0.00% | 35.3K | 0.36% |
| 2 | Dimensional - International Small Cap Value ETF DISV | 0.00% | 7.6K | 0.42% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Akira Iwasaki | President, Executive Vice President, GM of Business Support Office & Director | — | male |
| Katsuharu Imi | Director, GM of Technology Headquarters & GM of Research Laboratories | — | male |
| Ken Okajima | Director, GM of General Affairs & Human Resources and GM of Internal Control & Audit Department | — | male |
| Motoyuki Ise | Director & GM of Production Headquarters | — | male |
| Shunji Matsuo | MD, GM of Sales, Tokyo Branch of Sales, GM of Fine Chemicals & Functional Materials & Director | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 4113.T
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
